We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+28.71%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$158M
AUM Growth
+$14.7M
Cap. Flow
-$29.6M
Cap. Flow %
-18.69%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$40B
$87.6M 55.36%
1,909,317
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$66.8M 42.19%
6,500,349
-2,700,000
-29% -$29.6M
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$3.88M 2.45%
2,790,964

Similar funds

TRV GP II's Q1 2021 Portfolio in Review

As of Q1 2021, TRV GP II held 3 positions worth $158M, up 10% from $144M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $29.6M in Q1 2021, reducing 1 holding. Its largest reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $29.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q1 2021 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $29.6M.
  • TRV GP II's ten largest holdings make up 100% of its $158M portfolio in Q1 2021.
  • TRV GP II opened 0 new positions and closed 0 in Q1 2021.
  • TRV GP II's portfolio value rose 10% quarter-over-quarter to $158M.

Based on TRV GP II's 13F filing for Q1 2021, filed 12 May 2021.